01Identify the kind of period being claimed

ICH Q1A(R2), in its pharmaceutical context, distinguishes a shelf life tied to the product remaining within specification from a drug-substance retest period followed by reassessment. Both depend on defined storage conditions.ICH Q1A(R2) — Stability terminology (opens in a new tab)

These definitions help interpret terminology; they do not assign either period to a Novum research reagent. For the actual material, obtain the supplier’s stated meaning and evidence scope.

A retest statement should not silently become an expiry statement, or vice versa. Nor does a passing result at a later date automatically establish a new long-term interval.

The question in this article is the support behind the claim. The chronology of analysis, report issue and approval is a separate documentary question.

02Assess the attributes separately before combining the conclusion

ICH Q1E describes evaluating individual stability attributes and then making an overall assessment. Its proposed period should not exceed the period supported by any individual attribute. The guidance also considers variability between batches.ICH Q1E — Evaluation of stability data (opens in a new tab)

This offers a useful reading principle: a favourable result for one attribute cannot erase a limiting result for another. The conclusion needs to address the complete relevant specification.

If all three attributes are required, this hypothetical package does not establish a twelve-month conclusion merely because the assay has the longest record. The limiting evidence needs to be addressed.

The table is not a rule that every laboratory should assign six months. It illustrates why the longest individual result is an inadequate basis for the overall claim.

03Check whether the evidence covers the supplied material

The supporting record should identify the material form, formulation, packaging and scope of the studied lots. A period established for one presentation does not automatically describe a differently supplied preparation.

Keep the acceptance basis visible as well. A statement that a sample was “stable” is difficult to assess if the report does not explain which attributes were measured and what counted as acceptable.

Distinguish directly observed intervals from modelled extensions. Both may appear in a supporting package, but their different roles should remain clear to the reader.

04Ask for the unresolved support rather than inventing a period

A focused clarification asks which material and conditions the stated period covers, what event starts it and which stability evidence supports it. If a retest is intended, ask what reassessment and decision process is specified.

Preserve any unanswered points in the research record. An ambiguous statement should not be converted into a confident laboratory instruction simply to fill an inventory field.

The final assessment can be concise: the claim, the evidence that applies and the remaining gap. That gives a study team a usable basis for its material decision without pretending that a generic article assigns a valid expiry.